Skip to main content

Table 2 ANOVA results for the effect of ACPA, treatment and time on changes in RA outcomes

From: ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial

  Larsen   DAS28   HAQ   EuroQol   PCS   MCS  
Effects F P F P F P F P F P F P
ACPA 31.90 <0.001 4.02 0.045 7.25 0.007 9.72 0.002 4.07 0.044 2.29 0.131
Time 16.83 <0.001 1.26 0.288 1.37 0.251 0.70 0.550 0.80 0.493 0.65 0.584
Treatment 9.93 <0.001 1.71 0.163 17.76 <0.001 11.47 <0.001 5.67 0.001 1.92 0.124
ACPA*Treatment 7.05 <0.001 3.99 0.008 0.48 0.696 2.94 0.032 3.22 0.022 1.84 0.138
  1. F = F-statistic; P = P-value; ACPA*Treatment = ACPA*Treatment interaction term. ACPA, anti-citrullinated protein antibody; DAS28, disease activity scores on a 28-joint count; HAQ, Health Assessment Questionnaire; MCS, mental component summary; PCS, physical component summary; RA, rheumatoid arthritis.